On the public citation graph

Metabolic Parameters as Biomarkers of Response to Immunotherapy and Prognosis in Non-Small Cell Lung Cancer (NSCLC): A Real World Experience

https://doi.org/10.3390/cancers13071634
0 signed · 78 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2015.3638openalex-snapshot
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1007/s00259-011-1934-6openalex-snapshot
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer
inferredcites →https://doi.org/10.1007/s00259-013-2530-8openalex-snapshot
Volume-based assessment by 18F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer
inferredcites →https://doi.org/10.1007/s00259-016-3420-7openalex-snapshot
Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer
inferredcites →https://doi.org/10.1007/s00259-017-3740-2openalex-snapshot
EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies
inferredcites →https://doi.org/10.1007/s00259-018-4151-8openalex-snapshot
Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer
inferredcites →https://doi.org/10.1007/s00259-018-4211-0openalex-snapshot
Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy
inferredcites →https://doi.org/10.1007/s00259-019-04500-7openalex-snapshot
New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer
inferredcites →https://doi.org/10.1007/s00259-019-04615-xopenalex-snapshot
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
inferredcites →https://doi.org/10.1007/s00262-019-02387-9openalex-snapshot
Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer
inferredcites →https://doi.org/10.1007/s11548-012-0749-7openalex-snapshot
Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer
inferredcites →https://doi.org/10.1007/s13139-013-0232-6openalex-snapshot
The Prognostic Value of 18F-FDG PET/CT for Early Recurrence in Operable Breast Cancer: Comparison with TNM Stage
inferredcites →https://doi.org/10.1016/j.acra.2011.08.020openalex-snapshot
Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage IV Nonsurgical Small-cell Lung Cancer
inferredcites →https://doi.org/10.1016/j.acra.2012.07.002openalex-snapshot
Prognostic Value of Metabolic Tumor Burden from 18F-FDG PET in Surgical Patients with Non–small-cell Lung Cancer
inferredcites →https://doi.org/10.1016/j.ejrad.2012.07.009openalex-snapshot
Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy
inferredcites →https://doi.org/10.1016/s0140-6736(16)32517-xopenalex-snapshot
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
inferredcites →https://doi.org/10.1016/s0959-8049(99)00229-4openalex-snapshot
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations
inferredcites →https://doi.org/10.1038/nrclinonc.2018.29openalex-snapshot
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
inferredcites →https://doi.org/10.1038/s41419-017-0061-0openalex-snapshot
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
inferredcites →https://doi.org/10.1038/s41598-019-50079-2openalex-snapshot
18F-FDG uptake in PET/CT is a potential predictive biomarker of response to anti-PD-1 antibody therapy in non-small cell lung cancer
inferredcites →https://doi.org/10.1056/nejmoa1501824openalex-snapshot
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1504627openalex-snapshot
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1507643openalex-snapshot
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1056/nejmoa1606774openalex-snapshot
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1097/igc.0b013e318260a905openalex-snapshot
Prognostic Significance of Volume-Based Metabolic Parameters in Uterine Cervical Cancer Determined Using 18F-Fluorodeoxyglucose Positron Emission Tomography
inferredcites →https://doi.org/10.1097/mnm.0000000000001025openalex-snapshot
18F-FDG PET/CT in non-small-cell lung cancer patients
inferredcites →https://doi.org/10.1126/science.aaa1348openalex-snapshot
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
inferredcites →https://doi.org/10.1136/jitc-2020-000645openalex-snapshot
Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study
inferredcites →https://doi.org/10.1148/radiol.12111148openalex-snapshot
Prognostic Value of Whole-Body Total Lesion Glycolysis at Pretreatment FDG PET/CT in Non–Small Cell Lung Cancer
inferredcites →https://doi.org/10.1148/rg.2018180060openalex-snapshot
Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non–Small Cell Lung Cancer
inferredcites →https://doi.org/10.1245/s10434-009-0719-7openalex-snapshot
Prognostic Value of Metabolic Tumor Volume Measured by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Esophageal Carcinoma
inferredcites →https://doi.org/10.1245/s10434-013-3270-5openalex-snapshot
Prediction for Recurrence Using F-18 FDG PET/CT in Pathologic N0 Lung Adenocarcinoma After Curative Surgery
inferredcites →https://doi.org/10.21873/anticanres.12180openalex-snapshot
Association Between PD-L1 Expression and Metabolic Activity on 18F-FDG PET/CT in Patients with Small-sized Lung Cancer
inferredcites →https://doi.org/10.2214/ajr.14.13847openalex-snapshot
Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non–Small Cell Lung Cancer
inferredcites →https://doi.org/10.2967/jnumed.107.043414openalex-snapshot
Chemotherapy Response Evaluation with 18F-FDG PET in Patients with Non-Small Cell Lung Cancer
inferredcites →https://doi.org/10.2967/jnumed.108.058461openalex-snapshot
18F-FDG PET/CT as an Indicator of Progression-Free and Overall Survival in Osteosarcoma
inferredcites →https://doi.org/10.2967/jnumed.119.233056openalex-snapshot
Comparison Between 18F-FDG PET–Based and CT-Based Criteria in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
inferredcites →https://doi.org/10.3322/caac.21590openalex-snapshot
Cancer statistics, 2020
inferredcites →https://doi.org/10.3390/cancers12051163openalex-snapshot
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival
inferredcites →https://doi.org/10.3390/cancers12082234openalex-snapshot
Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab
inferredcites →https://doi.org/10.3390/jcm9030725openalex-snapshot
Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
inferredcites →https://doi.org/10.3747/co.26.4167openalex-snapshot
Metabolic Tumour Volume Is Prognostic in Patients with Non-Small-Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4114254openalex-extracted
inferred← citeshttps://doi.org/10.1007/s00330-024-10651-5openalex-snapshot
Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in resectable non-small cell lung cancer
inferred← citeshttps://doi.org/10.1007/s40336-026-00784-6openalex-snapshot
Predicting survival in non-small cell lung cancer treated with nivolumab: the role of spleen and bone marrow 18 F-FDG PET/CT parameters
inferred← citeshttps://doi.org/10.1016/j.cllc.2022.02.003openalex-snapshot
Disease Burden on PET Predicts Outcomes for Advanced NSCLC Patients Treated with First-Line Immunotherapy
inferred← citeshttps://doi.org/10.1016/j.ejrad.2022.110200openalex-snapshot
The role of PET molecular imaging in immune checkpoint inhibitor therapy in lung cancer: Precision medicine and visual monitoring
inferred← citeshttps://doi.org/10.1016/j.lungcan.2022.01.001openalex-snapshot
Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection
inferred← citeshttps://doi.org/10.1053/j.ro.2025.06.002openalex-snapshot
Quantitative Imaging Biomarkers in Lung Cancer: Current Trends and Future Directions
inferred← citeshttps://doi.org/10.1053/j.semnuclmed.2022.04.007openalex-snapshot
The Value of the Standardized Uptake Value (SUV) and Metabolic Tumor Volume (MTV) in Lung Cancer
inferred← citeshttps://doi.org/10.1111/1759-7714.70342openalex-snapshot
Guiding the Application of Immunotherapy in Nonsmall Cell Lung Cancer: The Role of Biomarkers
inferred← citeshttps://doi.org/10.1136/jitc-2023-007628openalex-snapshot
Total metabolic tumor volume on 18 F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy
inferred← citeshttps://doi.org/10.1177/17588359221138386openalex-snapshot
Tumor Glycolytic Profiling Through 18F-FDG PET/CT Predicts Immune Checkpoint Inhibitor Efficacy in Advanced NSCLC
inferred← citeshttps://doi.org/10.1177/17588359241293364openalex-snapshot
The role of baseline 18 F-FDG PET/CT for survival prognosis in NSCLC patients undergoing immunotherapy: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1186/s40644-024-00745-0openalex-snapshot
DCE-CT parameters as new functional imaging biomarkers at baseline and during immune checkpoint inhibitor therapy in patients with lung cancer – a feasibility study
inferred← citeshttps://doi.org/10.1186/s41824-022-00158-xopenalex-snapshot
Volumetric parameters of the primary tumor and whole-body tumor burden derived from baseline 18F-FDG PET/CT can predict overall survival in non-small cell lung cancer patients: initial results from a single institution
inferred← citeshttps://doi.org/10.12122/j.issn.1673-4254.2023.12.20openalex-snapshot
[Construction of a prognostic nomogram combining PET/CT metabolic parameters and blood inflammatory markers for non-small cell lung cancer treated with first-line chemotherapy].
inferred← citeshttps://doi.org/10.21037/atm-22-1475openalex-snapshot
DNAJC12 activated by HNF1A enhances aerobic glycolysis and drug resistance in non-small cell lung cancer
inferred← citeshttps://doi.org/10.21203/rs.3.rs-7907062/v1openalex-snapshot
Predict the prognosis of patients with non-small cell lung cancer based on CT radiomics and clinical pathological factors
inferred← citeshttps://doi.org/10.2147/cmar.s522136openalex-snapshot
Advances in Multimodal Imaging Techniques for Evaluating and Predicting the Efficacy of Immunotherapy for NSCLC
inferred← citeshttps://doi.org/10.3389/fgene.2021.810011openalex-snapshot
Potentials of Non-Invasive 18F-FDG PET/CT in Immunotherapy Prediction for Non–Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.3389/fimmu.2022.1004351openalex-snapshot
Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer
inferred← citeshttps://doi.org/10.3389/fimmu.2023.1093974openalex-snapshot
Comprehensive analysis of the prognosis, tumor microenvironment, and immunotherapy response of SDHs in colon adenocarcinoma
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1896967openalex-snapshot
Prognostic superiority of volumetric PET parameters (MTV and TLG) over SUV in advanced non-small-cell lung cancer: a systematic review and meta-analysis of univariate and multivariate evidence
inferred← citeshttps://doi.org/10.3389/fonc.2022.951557openalex-snapshot
Predictive value of baseline metabolic tumor volume for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
inferred← citeshttps://doi.org/10.3389/fonc.2024.1530507openalex-snapshot
Innovative applications and future trends of multiparametric PET in the assessment of immunotherapy efficacy
inferred← citeshttps://doi.org/10.3389/fonc.2025.1651843openalex-snapshot
The value of 18F-FDG PET/CT imaging in predicting the efficacy of PD-1/PD-L1 immune checkpoint inhibitors in advanced non-small cell lung cancer
inferred← citeshttps://doi.org/10.3390/cancers13133117openalex-snapshot
The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab
inferred← citeshttps://doi.org/10.3390/cancers13184543openalex-snapshot
NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images
inferred← citeshttps://doi.org/10.3390/cancers13236096openalex-snapshot
First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes
inferred← citeshttps://doi.org/10.3390/cancers14010058openalex-snapshot
Advances in Lung Cancer Imaging and Therapy
inferred← citeshttps://doi.org/10.3390/cancers14246095openalex-snapshot
Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors
inferred← citeshttps://doi.org/10.3390/diagnostics11091681openalex-snapshot
Immune Checkpoint Inhibitors in Advanced NSCLC: [18F]FDG PET/CT as a Troubleshooter in Treatment Response
inferred← citeshttps://doi.org/10.3390/jcm12113725openalex-snapshot
Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition
inferred← citeshttps://doi.org/10.3390/life13041051openalex-snapshot
Assessment of the Association between Entropy in PET/CT and Response to Anti-PD-1/PD-L1 Monotherapy in Stage III or IV NSCLC
inferred← citeshttps://doi.org/10.3779/j.issn.1009-3419.2024.101.26openalex-snapshot
[Advances in the Application of Adjuvant Chemotherapy and Targeted Therapy in Postoperative Patients with Stage I Lung Adenocarcinoma].
inferred← citeshttps://doi.org/10.4236/abb.2023.144010openalex-snapshot
Value of 18F-FDG PET/CT Based on PD-L1 to Predict Outcomes of Immunotherapy in NSCLC
inferred← citeshttps://doi.org/10.7717/peerj.16807openalex-snapshot
Prognostic significance of integrating total metabolic tumor volume and EGFR mutation status in patients with lung adenocarcinoma
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.